{"filings":[{"id":889209,"accession_number":"0001193125-26-259703","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-06-05T20:30:16+00:00","items":["1.01","9.01"],"status":"ready","headline":"Plus Therapeutics enters into $17.35M ATM equity distribution agreement with Canaccord Genuity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Up to $17.35M of common stock may be sold at-the-market through Canaccord Genuity as agent.","Commission of 3.0% of gross proceeds plus $75,000 expense reimbursement to Agent.","Proceeds intended for general corporate purposes and working capital.","Sales may be made on Nasdaq Capital Market under Rule 415; no obligation to sell shares.","Offering terminates upon sale of all shares or termination of Distribution Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":472156,"accession_number":"0001193125-26-227059","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-05-15T20:46:48+00:00","items":["5.07"],"status":"ready","headline":"Plus Therapeutics holds annual meeting post 1-for-25 reverse split; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six directors elected; votes for ranged from 11.9M to 12.4M; broker non-votes ~50.8M.","Ratification of CBIZ CPAs as auditor for 2026 approved with 60.9M in favor.","Advisory say-on-pay approved with 10.4M for, 3.4M against.","Sixth amendment to 2020 Stock Incentive Plan approved (7.98M for, 5.65M against).","Meeting held after 1-for-25 reverse split effective April 2, 2026; vote results on pre-split share count."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":470998,"accession_number":"0001193125-26-226747","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-05-15T20:13:11+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q1 net loss $6.9M; REYOBIQ gets FDA Orphan Drug Designation","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $15.1M as of March 31, 2026, up from $8.6M at Dec 2025 after $15M public offering.","Net loss $6.9M ($1.05 per share) vs $17.4M in Q1 2025 (post reverse split).","Revenue $1.0M from CPRIT grant and CNSide billings; operating loss $7.1M vs $3.5M year ago.","FDA granted Orphan Drug Designation for REYOBIQ in pediatric malignant gliomas and ependymoma.","CNSide expanded payer coverage to ~81M lives including Blue Shield of California; unique PLA code secured."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91262,"accession_number":"0001193125-26-165205","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Plus Therapeutics regains Nasdaq minimum bid price compliance after 1-for-25 reverse split","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Plus Therapeutics on April 20, 2026 that bid price closed at or above $1.00 for 10 consecutive days through April 17.","Reverse stock split (1-for-25) was effective April 2, 2026 and enabled compliance with Listing Rule 5550(a)(2).","Nasdaq has closed the matter; PSTV common stock remains listed on The Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91261,"accession_number":"0001193125-26-148920","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Plus Therapeutics appoints Eric J. Daniels as CDO; base salary $460K, equity grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniels becomes Chief Development Officer effective April 20, 2026, reporting to CEO.","Prior role: Chief Development Officer at Kiora Pharmaceuticals (NASDAQ:KPRX) from Oct 2021 to Apr 2026.","Initial annual base salary of $460,000; target bonus of 40% of base salary.","Equity inducement: option for 20,000 shares vesting over 4 years (1-yr cliff) and 20,000 RSUs vesting over 3 years.","Severance on involuntary termination: 12 months' salary plus target bonus, plus vesting acceleration on 9 months of unvested equity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91260,"accession_number":"0001193125-26-146335","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-04-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Plus Therapeutics' REYOBIQ gets FDA Orphan Drug Designation for pediatric malignant gliomas","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["ODD covers pediatric malignant gliomas including ependymoma, broader than originally requested.","Designation provides 7 years of market exclusivity upon approval, tax credits, and fee exemptions.","Follows FDA Type B meeting supporting development in leptomeningeal metastases and IND clearance for pediatric high-grade glioma and ependymoma.","REYOBIQ delivers targeted radiotherapy to CNS tumors while minimizing healthy brain exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":91259,"accession_number":"0001193125-26-140267","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-04-02T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"Plus Therapeutics approves 1-for-25 reverse stock split to meet Nasdaq $1.00 minimum bid price","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-25, effective 12:01 a.m. ET on April 2, 2026; shares drop from ~171.6M to ~6.86M.","Action taken to increase per-share price above Nasdaq's $1.00 minimum bid requirement for continued listing.","No fractional shares issued; cash in lieu; new CUSIP 72941H806; trading symbol stays PSTV.","Broadridge acts as exchange agent; book-entry holders need no action; certificates receive instructions.","Par value unchanged at $0.001; proportional adjustments to equity awards and warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101244,"accession_number":"0001193125-26-125195","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-03-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Plus Therapeutics appoints Ronald A. Andrews to board; Robert Lenk resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert Lenk resigned as director and Nominating Committee member effective March 20, 2026; no policy disagreement cited.","Ronald A. Andrews appointed to fill vacancy, effective immediately; will stand for reelection at 2026 annual meeting.","Andrews is independent under Nasdaq rules; appointed to Nominating and Corporate Governance Committee.","Andrews brings 35+ years in diagnostics; currently Founder/Managing Partner of The Bethesda Group.","No transactions requiring SEC disclosure; standard indemnification agreement expected."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101243,"accession_number":"0001193125-26-104291","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Plus Therapeutics sets 2026 annual meeting for May 14; proxy deadlines March 22","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Annual meeting scheduled for May 14, 2026 at 9:00 a.m. ET, held virtually.","Record date for stockholders is March 18, 2026.","Deadline for Rule 14a-8 stockholder proposals and director nominations: March 22, 2026.","Meeting date is more than 30 days before 2025 anniversary, rendering prior proxy deadlines void.","Universal proxy rule compliance notice also due by March 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101242,"accession_number":"0001193125-26-104218","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics FY2025 net loss $22.4M; cash $13.1M, outlines 2026 milestones for REYOBIQ and CNSide","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $22.4M ($0.29/shr) vs $13.0M ($1.95/shr) in 2024; operating loss $15.3M vs $14.7M.","Cash and investments $13.1M at Dec 31, 2025 (up from $3.6M); raised $15M gross in upsized public offering.","CNSide lab licensed in 49 states; coverage agreements with Humana and UnitedHealthcare reach ~67M lives.","2026 milestones: REYOBIQ Phase 2 LM data Q3 2026, GBM data Q4; CNSide target >1,250 annual test orders, breakeven by 2027.","Secured AMA Category III CPT code for convection-enhanced delivery with REYOBIQ, unlocking market access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101241,"accession_number":"0001193125-26-051379","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-02-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Plus Therapeutics Approves FY2025 Cash Bonuses: CEO Hedrick Gets $305,663, CFO Sims Gets $149,175","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["On Feb 9, 2026, Compensation Committee approved discretionary cash bonuses for Named Executive Officers for FY2025.","CEO Marc H. Hedrick received a $305,663 cash bonus; total 2025 compensation was $5,566,732.","CFO Andrew Sims received a $149,175 cash bonus; total 2025 compensation was $1,631,279.","Former CMO Norman LaFrance, who stepped down in June 2024, received $0 compensation in FY2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101240,"accession_number":"0001193125-26-018675","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Plus Therapeutics updates corporate presentation; no specific new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Filed updated investor presentation under Item 8.01.","Presentation slides filed as Exhibit 99.1, but no material changes evident from filing text.","No financial results, guidance, or operational milestones mentioned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101239,"accession_number":"0001193125-26-015346","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Plus Therapeutics prices $15M public offering of 39.5M units at $0.38; net ~$13.3M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 39,473,684 units at $0.38 each, each unit = one share + one warrant.","Gross proceeds $15M; net proceeds ~$13.3M after underwriting discounts and expenses.","Underwriter exercised over-allotment for additional 5,921,052 warrants.","Warrants immediately exercisable at $0.38 per share, expire in 5 years.","Proceeds for working capital; 45-day insiders lock-up and 120-day ban on variable rate transactions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117594,"accession_number":"0001193125-25-283935","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-11-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Plus Therapeutics gets Nasdaq extension until May 11, 2026 to regain $1 bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received 180-day extension to May 11, 2026 from Nasdaq to meet $1.00 minimum bid price rule.","No immediate effect on listing; stock continues trading on Nasdaq under PSTV.","If bid price closes at $1.00+ for 10 consecutive days, compliance confirmed and matter closed.","Company may implement reverse stock split if needed; no guarantee of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117593,"accession_number":"0001193125-25-258568","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q3 net loss $0.04/shr; cash $16.6M; CNSide commercial launch advances","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.4M ($0.04/shr) vs $2.9M ($0.37/shr) in Q3 2024; operating loss $4.5M.","Cash and investments $16.6M (up from $6.9M on June 30, 2025 and $3.6M at Dec 31, 2024).","First national coverage agreement with UnitedHealthcare for CNSide diagnostics, covering 51M+ lives.","Houston lab received CLIA certification, enabling Medicare/Medicaid access and commercial payor coverage.","Positive ReSPECT-LM Phase 1 results for REYOBIQ presented at SNO/ASCO; advance payment of $1.9M from CPRIT."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":3846000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":117592,"accession_number":"0001193125-25-244275","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Plus Therapeutics signs 11,370 sq ft lease in Houston; $58,745/mo base rent, 10-yr term starting Nov 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease covers 11,370 rentable square feet on third floor of 6420 Levit Green Blvd, Houston; 120-month term.","Monthly base rent starts at $58,745, increasing 3% annually; plus share of operating expenses.","Tenant also leases temporary space (Suite 210) at same monthly rent from Oct 16, 2025 until permanent space is ready; first 3 months' rent deferred.","Security deposit and certain terms redacted; parking includes 34 unreserved spaces.","Lease with LG 1 Property Owner LP; Tenant represented by no broker."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134024,"accession_number":"0001193125-25-188075","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Plus Therapeutics regains Nasdaq compliance on two listing rules; bid price deadline extended to Nov 12, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq confirmed compliance with MVLS ($35M) and equity ($2.5M) standards on Aug 22, 2025.","Bid price rule deadline extended to Nov 12, 2025; prior Sept 8 deadline no longer applies.","One-year monitoring for equity standard through Aug 22, 2026; breach triggers delist process without cure period.","Company now satisfies two alternative criteria under Nasdaq Listing Rule 5550."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134023,"accession_number":"0001193125-25-180814","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Plus Therapeutics Regains Nasdaq Compliance; Reports $3M Stockholders' Equity and $35M+ MVLS","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Reported stockholders' equity of $3M as of June 30, 2025, satisfying Nasdaq's minimum $2.5M Equity Rule.","Sold over $2M in common stock via a $50M equity line of credit with Lincoln Park Capital Fund since June 30.","As of August 13, 2025, market value of listed securities exceeded $35M for 20 consecutive business days, meeting the alternative MVLS requirement.","Company awaits formal Nasdaq confirmation that it has evidenced compliance with either or both listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134022,"accession_number":"0000950170-25-108854","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q2 2025: net income $5.2M on derivative gain; CNSide assay launched in Texas","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $6.9M at June 30, 2025 vs $3.6M at Dec 31, 2024; operating loss $1.5M vs $3.7M in Q2 2024.","Net income $5.2M ($0.02 diluted) vs net loss $2.9M ($0.45 loss) in Q2 2024; derivative gain of $6.5M pre-tax.","CNSide CSF assay launched in Texas in Aug 2025; TAM estimated $6B; additional states planned late 2025-2026.","REYOBIQ dose optimization trial started; FDA IND clearance for pediatric high-grade glioma and ependymoma.","Received $1.6M advance from $17.6M CPRIT grant; added industry veteran Kyle Guse to Board of Directors."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":2449000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134021,"accession_number":"0001193125-25-179382","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Plus Therapeutics updates Nasdaq listing; panel grants continued listing with conditions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq panel granted continued listing; must demonstrate $2.5M stockholders' equity compliance by Aug 14, 2025.","Must also meet $1.00 bid price for 10 consecutive days by Sep 8, 2025.","Company reported stockholders' deficit of $23.6M as of March 31, 2025, triggering delisting notice.","Hearing held July 15, 2025; panel decision issued July 22, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134020,"accession_number":"0001193125-25-179012","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Plus Therapeutics shareholders approve reverse stock split authorization and up to $50M issuance to Lincoln Park","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees were elected to the board for a term expiring at the 2026 annual meeting.","Approved potential issuance of up to $50M common stock plus $1M commitment fee to Lincoln Park Capital Fund.","Board authorized to effect a reverse stock split at a ratio between 1:2 and 1:250 within 12 months.","Advisory vote on executive compensation passed with 16,714,842 votes for and 858,028 against.","Fifth amendment and restatement of the 2020 Stock Incentive Plan was approved by stockholders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134019,"accession_number":"0001193125-25-161239","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-07-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Plus Therapeutics dismisses BDO, engages CBIZ as new auditor; prior reports note going concern","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee dismissed BDO USA, P.C. as independent auditor on July 16, 2025.","Engaged CBIZ CPAs P.C. as new independent registered public accounting firm effective immediately.","BDO's 2023 and 2024 audit reports included a going-concern explanatory paragraph; no disagreements.","Material weakness in internal control over grant revenue accounting was disclosed for FY2023.","No reportable events or disagreements occurred during the two most recent fiscal years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150772,"accession_number":"0001193125-25-143665","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-06-20T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Plus Therapeutics enters $50M common stock purchase agreement with Lincoln Park Capital","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plus Therapeutics signed a purchase agreement with Lincoln Park Capital for up to $50 million of common stock over 36 months.","Lincoln Park commits to buy up to 300,000 shares per regular purchase (up to 500,000 at higher prices) at 97% of market price.","The company will pay a $500,000 initial commitment fee in cash or stock, plus $500,000 after reaching $25 million in sales.","Proceeds will fund working capital and a $17.3 million make-whole repayment to March 2025 warrant holders.","Issuance beyond 10,194,593 shares requires shareholder approval unless average sale price exceeds $0.3576."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150771,"accession_number":"0001193125-25-142093","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-06-17T23:59:59+00:00","items":["1.01","3.03","9.01"],"status":"ready","headline":"Plus Therapeutics cuts Series B warrant shares from 1.26B to 35.5M; cancels Series A warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cancelled all Series A warrants exercisable for up to 280M shares of common stock.","Series B warrants amended to reduce total shares issuable from ~1.26B to ~35.5M; cashless exercise ratio cut from 3:1 to 1:1.","Investors agreed to return ~12.2M Private Placement Shares and Pre-Funded Warrants in exchange for 115% repayment from future capital raises.","Registration Rights Agreement terminated; restrictions on subsequent equity sales waived."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150770,"accession_number":"0001193125-25-137089","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Plus Therapeutics gets Nasdaq delisting notice for negative stockholders' equity","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Company reported stockholders' equity deficit of $23.6M as of March 31, 2025, failing Nasdaq's $2.5M minimum.","Nasdaq staff determined to delist securities; company must request a hearing by June 10, 2025.","Common stock (PSTV) continues trading on Nasdaq Capital Market pending hearing decision.","Company plans to appeal; hearing typically scheduled 30-45 days after request.","Previously regained compliance on equity requirement on March 7, 2025, but fell back into non-compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150769,"accession_number":"0000950170-25-079749","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-05-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q1 net loss $17.4M; cash jumps to $9.9M on $15M financing and grants","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash balance $9.9M at Mar 31, 2025 vs $0.1M at Dec 31, 2024; raised $15M private placement and $2M grant advance.","Net loss $17.4M ($1.19/share) vs $3.3M ($0.75/share) in Q1 2024; operating loss $3.5M vs $3.3M.","Completed ReSPECT-LM Phase 1 dose trial; FDA Orphan Drug Designation for REYOBIQ for leptomeningeal metastases in lung cancer.","Published Phase 1 REYOBIQ data in Nature Communications: >100 Gy dose group median OS 17 months, double standard of care.","Added board member Kyle Guse; management hires: Dr. Rosol (CDO), Bradley (CNSide President), Stein (Medical Director)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":1059000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150768,"accession_number":"0001193125-25-125860","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01","7.01","9.01"],"status":"ready","headline":"Plus Therapeutics receives Nasdaq deficiency notice for late Q1 10-Q filing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on May 21, 2025 for missing Q1 2025 Form 10-Q filing deadline.","Must submit a plan to regain compliance by July 21, 2025.","If plan accepted, Nasdaq can grant exception until November 17, 2025 to file.","No immediate effect on PSTV stock listing on Nasdaq.","Company expects to return to normal filing cadence for remainder of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150767,"accession_number":"0000950170-25-074374","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-05-19T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Plus Therapeutics receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Plus Therapeutics on May 16, 2025 of non-compliance with minimum bid price rule (closing bid < $1.00 for 30 consecutive days).","Initial compliance period ends November 12, 2025; must close at $1.00+ for 10 consecutive business days.","If not cured by Nov 12, may be eligible for additional 180-day period if meets other listing standards.","Company will consider options including reverse stock split to regain compliance; no assurance of success.","Potential delisting can be appealed; common stock continues trading on Nasdaq during process."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150766,"accession_number":"0000950170-25-062742","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"Plus Therapeutics stockholders approve 20x authorized share increase to 2B; massive dilution authorized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 100M to 2B; reverse split authorized at ratio between 1:25 and 1:250.","Stockholders approved issuance of up to 1.26B shares upon exercise of Series B Warrants with zero exercise price.","Warrant exercise price reset to floor of $0.132; Series A/B could total ~1.68B shares if fully exercised.","All proposals passed with >88% votes for; quorum of 8.2M shares out of 11.8M outstanding.","Item 8.01 confirms massive potential equity dilution from prior private placement warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":150765,"accession_number":"0000950170-25-055883","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Plus Therapeutics appoints Kyle Guse to board; Greg Petersen resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kyle Guse appointed to board effective April 18, 2025, filling vacancy from Greg Petersen's resignation.","Guse named to Audit Committee (Chair) and Compensation Committee; board deemed independent under Nasdaq rules.","Greg Petersen resigned same day; no disagreement with company operations, policies, or practices.","Guse is Chief Legal Officer at DDC Enterprise; previously CFO/GC at Atossa Therapeutics.","Guse brings 30 years of experience in finance, corporate governance, and M&A; will stand for reelection."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169711,"accession_number":"0000950170-25-046110","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics reports 2024 net loss of $13.0M, cash $3.6M; raised $15M in private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $3.6M at Dec 31, 2024 vs $8.6M at Dec 31, 2023.","Net loss $13.0M ($1.95 per share) in 2024 vs $13.3M ($4.24 per share) in 2023; operating loss $14.7M.","Raised $15.0M via private placement, regains Nasdaq compliance and extends runway into 2026.","FDA agreed on brand name REYOBIQ; orphan drug designation for leptomeningeal metastases in lung cancer.","Appointed Dr. Michael Rosol as Chief Development Officer; Russell Bradley as President/GM of CNSide Diagnostics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169710,"accession_number":"0001193125-25-050390","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-03-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Plus Therapeutics regains Nasdaq minimum equity compliance after private placement","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter dated March 7, 2025 confirming compliance with minimum stockholders' equity requirement (Rule 5550(b)(1)).","Compliance achieved via private placement disclosed on March 4, 2025; escrow funds now released to the company.","Subject to Mandatory Panel Monitor until March 7, 2026; any future non-compliance triggers immediate delisting without cure period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169709,"accession_number":"0001193125-25-045305","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-03-04T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Plus Therapeutics raises $15M in private placement; exchanges $3.2M in convertible notes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement of ~28M shares (or prefunded warrants) at $0.66/unit, each with Series A and B warrants.","Gross proceeds of ~$15M; includes exchange of $3.2M convertible notes for securities in the placement.","Company repurchases $3.4M in notes and 3M warrants for $4.25M, eliminating financing restrictions.","Believes it has regained compliance with Nasdaq minimum stockholders' equity requirement (Rule 5550(b)(1)).","Closing contingent on Nasdaq confirmation by March 31, 2025; funds held in escrow pending."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":169708,"accession_number":"0001193125-25-028151","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Plus Therapeutics raises ~$3.7M in secured convertible notes, exchanges warrants, and receives $2M CPRIT advance","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $3.36M in secured convertible notes and warrants to purchase ~3M shares at $1.12; aggregate proceeds ~$3.7M.","Exchanged $3.19M of existing Series A warrants for new secured convertible exchange notes.","Notes mature Feb 2026, 10% interest, secured by substantially all assets; mandatory conversion if $10M+ qualified financing by March 31, 2025.","Received $2.0M advance from CPRIT as part of existing $17.6M grant.","Registration rights with liquidated damages of 1%/month (12% cap) for filing/effectiveness delays."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186757,"accession_number":"0000950170-24-127067","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.","Cash and investments $4.8M at Sep 30, down from $8.6M at Dec 31, 2023; subsequent $0.9M DoD grant, $3.9M CPRIT grant expected.","FDA agreed to initiate Phase 1 multi-dose trial of Rhenium(186Re) Obisbemeda for leptomeningeal metastases (LM); enrollment starts early 2025 at 7 U.S. sites.","Completed enrollment in ReSPECT-GBM Phase 1 trial; presented positive data at CNS 2024; expanded sites to North Shore and Ohio State.","Established GMP manufacturing partnership with SpectronRx for late-stage clinical and commercial supply of Rhenium(186Re) Obisbemeda."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":4412000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186756,"accession_number":"0001193125-24-249270","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-11-01T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Plus Therapeutics receives Nasdaq extension until March 4, 2025 to regain minimum equity compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Hearings Panel granted extension to March 4, 2025 for Plus Therapeutics to meet $2.5M stockholders' equity minimum.","Company has been non-compliant since March 8, 2024; hearing was held on October 22, 2024.","No assurance of regaining compliance; delisting risk remains if equity condition not met by deadline.","Stock continues trading on Nasdaq Capital Market under ticker PSTV during extension period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203312,"accession_number":"0001193125-24-215218","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Plus Therapeutics receives Nasdaq delisting notice; plans appeal to stay listing","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified on Sept 5, 2024 that company failed to regain compliance with minimum $2.5M stockholders' equity rule.","Company intends to timely appeal, which automatically stays suspension/delisting pending hearing.","Prior disclosure: stockholders' equity was ($1.348M) as of Dec 31, 2023.","No assurance that Nasdaq Hearings Panel will grant continued listing or extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203311,"accession_number":"0001193125-24-201372","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-08-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Plus Therapeutics stockholders elect all six director nominees and ratify auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected: Clowes, van Es-Johansson, Hawkins, Hedrick, Lenk, Petersen. Votes For ranged 1.16M-1.18M.","Ratification of BDO USA as auditor for FY2024 approved: 2.43M For, 44,854 Against.","Advisory say-on-pay approved: 1.12M For, 163,917 Against.","Fourth amendment and restatement of 2020 Stock Incentive Plan approved: 1.10M For, 182,432 Against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":203310,"accession_number":"0000950170-24-097001","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q2 2024: ReSPECT-LM Phase 1 shows median OS 12 months; net loss $6.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["ReSPECT-LM Phase 1 safe in 16 patients; median overall survival 12 months, 8 of 16 alive.","CNSide diagnostic met primary endpoint: helped clinical decisions in >90% of cases; tumor cell detection 80% vs 29% cytology.","Received $3.3M CPRIT grant in June 2024 for Rhenium (186Re) Obisbemeda development.","Cash $8.4M at June 30; H1 net loss $6.2M ($1.15/share) vs $6.3M ($2.60/share) year ago.","Upcoming: complete ReSPECT-LM Phase 1 single-dose, initiate multiple-dose Phase 1, and IND for pediatric trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":2956000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219676,"accession_number":"0000950170-24-070569","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Plus Therapeutics CMO Dr. Norman LaFrance resigns effective June 12, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Norman LaFrance resigned as Chief Medical Officer on June 5, 2024.","Resignation effective June 12, 2024; no reason provided in the filing.","No successor or interim CMO announced; President & CEO Marc Hedrick signs 8-K.","Company trades on Nasdaq under ticker PSTV."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219675,"accession_number":"0001193125-24-154380","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-06-04T23:59:59+00:00","items":["1.01","1.02","2.03","9.01"],"status":"ready","headline":"Plus Therapeutics draws $3.3M from Pershing facility to repay Oxford term loan in full","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Drew $3.3M from Pershing margin loan facility at FOMC target (floor 5.5%) + 1.75% spread + 0.5% fees, max Prime+3%.","On June 3, 2024, used the draw to repay and terminate the Oxford Finance term loan, totaling approx. $3.3M.","Repayment eliminated Oxford's security interest in all of Plus Therapeutics' assets and related covenants.","Pershing credit line is secured by collateralized marketable securities; can draw up to 91.5% of collateral value.","Outstanding balance is due on demand; Pershing may require additional collateral or liquidate securities upon default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219674,"accession_number":"0000950170-24-062116","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["5.08","8.01"],"status":"ready","headline":"Plus Therapeutics sets 2024 annual meeting for August 15; stockholder proposals due May 30","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting to be held virtually on August 15, 2024 at 9:00 a.m. Eastern Time.","Record date for stockholders entitled to vote is June 25, 2024.","Stockholder proposals and director nominations must be received by May 30, 2024 at 5:00 p.m. ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219673,"accession_number":"0000950170-24-060399","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q1 2024 net loss $3.3M; cash $3M; secures up to $19.25M financing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.3M ($0.75 per share) vs $4.8M ($2.07) in Q1 2023; grant revenue rose to $1.7M from $0.5M.","Cash balance $3.0M at March 31, 2024, down from $8.6M at December 31, 2023.","Closed private placement for initial $7.25M with potential total of $19.25M from healthcare funds and insiders.","Received $3M Department of Defense grant recommendation for Phase 1 rhenium obisbemeda trial in pediatric brain cancer.","Acquired exclusive rights to CNSide leptomeningeal metastases diagnostic; reported positive top-line FORESEE trial data."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.75,"consensus_revenue_estimate":null,"consensus_revenue_actual":1677000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":219672,"accession_number":"0001193125-24-135399","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"PSTV raises $7.25M via private placement of shares and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $7.25M from private placement of 3,591,532 units at $2.022/$2.158 per unit.","Units consist of one share (or pre-funded warrant) plus Series A and Series B warrants.","Series A warrants exercisable for 5 years, Series B warrants exercisable for 1 year after registration effectiveness.","Potential additional proceeds up to $12M from warrant exercises.","Insiders purchased $98,500 of securities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239469,"accession_number":"0001193125-24-068002","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-03-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Plus Therapeutics receives Nasdaq delisting notice for equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity was ($1,348,000) as of Dec 31, 2023, below Nasdaq's $2.5M minimum.","Company has 45 days (until Apr 22, 2024) to submit a plan to regain compliance.","If accepted, Nasdaq may grant up to 180 days (until Sep 4, 2024) to cure the deficiency.","Company plans to pursue capital raising to satisfy the equity or alternative standards.","Failure to regain compliance could result in delisting of PSTV common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239468,"accession_number":"0001193125-24-066407","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Plus Therapeutics CEO presents at JonesResearch webcast; no material new details in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["CEO Marc Hedrick presented at a JonesResearch webcast on March 12, 2024.","Presentation slides filed as Exhibit 99.1 but no specific financial or operational data extracted from filing text.","Slides to be used in upcoming investor meetings as part of Regulation FD disclosure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":239467,"accession_number":"0000950170-24-025866","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2024-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics reports FY2023 net loss $13.3M; cash $8.6M; ReSPECT-LM advances to Cohort 5","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $(13.3)M ($4.24 per share) vs $(20.3)M ($11.58 per share) in 2022; operating loss improved to $13.3M from $19.7M.","Cash at Dec 31, 2023 was $8.6M, down from $18.1M; runway forecast into 2H 2025.","Enrolled 5th of 7 dosing cohorts in ReSPECT-LM Phase 1 trial for leptomeningeal metastases; orphan drug designation granted for breast cancer LM.","Received $3.3M advance from CPRIT grant ($17.6M total); total grant revenue recognized $4.9M in 2023.","Plans FDA meetings in 2024 to align on pivotal trial design for LM and GBM; registrational trial target 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256996,"accession_number":"0001193125-23-280212","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2023-11-20T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Plus Therapeutics Phase 2 GBM trial: mOS 13 mo (63% above SOC), mPFS 11 mo","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Median overall survival 13 months in 15 rGBM patients, 63% better than SOC bevacizumab (8 mo).","Median progression-free survival 11 months vs SOC 4 months; 9 of 15 patients remain alive.","Delivers up to 20x radiation dose (740 Gy) vs EBRT (35 Gy); favorable safety profile maintained.","Imaging analysis confirms efficacy signal; company to host KOL webinar Nov 20 at 10 am ET."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256995,"accession_number":"0001193125-23-267279","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Plus Therapeutics board authorizes $500K share repurchase program","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved repurchase of up to $500,000 of common stock over 12 months.","Repurchases may be made on open market or privately, subject to lender consent.","Company not obligated to buy any shares; program can be discontinued at any time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":256994,"accession_number":"0001193125-23-267200","cik":1095981,"company_name":"PLUS THERAPEUTICS, INC.","ticker":"PSTV","form_type":"8-K","filed_at":"2023-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Plus Therapeutics Q3 net loss $3.2M ($1.00/share); cash $11M, runway into 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $3.2M ($1.00 per share) vs $5.2M ($2.85) in Q3 2022; operating expenses $4.5M.","Cash $11M at Sep 30, 2023; plus $10.2M expected from CPRIT grant through 2024, providing runway into 2025.","Completed dosing in Cohort 4 of Phase 1 ReSPECT-LM trial; new survival data from Phase 2 ReSPECT-GBM to be presented at SNO Nov 2023.","Appointed Pius Maliakal, Ph.D. as VP of Clinical Operations; transferred CNSide biomarker assay from Biocept.","Grant revenue $1.2M in Q3 from CPRIT; total grant awards $3M from NIH and $17.6M from CPRIT."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":45703821.22424243,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-10-31T23:59:59+00:00|256994"}